Triple combination cancer immunotherapy improves outcomes in preclinical melanoma model

In adoptive cell transfer immunotherapy, T cells able to recognize a tumor are harvested, expanded in the laboratory, and then reintroduced to attack the tumor. However, they often do not persist long enough to finish the job. A triple combination regimen of adoptive T cell transfer, a PIM kinase inhibitor, and a PD1 inhibitor improved T cell persistence and tumor control in a mouse model of melanoma, report investigators. (Mehr in: Cancer News — ScienceDaily)